Percutaneously absorptive ophthalmic preparation comprising olopatadine
The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.
1. A method for delivering olopatadine or a pharmaceutically acceptable salt thereof to an anterior ocular segment of a mammalian subject, which comprises applying a percutaneously absorptive preparation comprising 5 to 30% by weight of olopatadine or a pharmaceutically acceptable salt thereof to the skin surface including the surface of an eyelid of the subject, thereby causing transfer of a therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof from the preparation to the anterior ocular segment of the subject,
wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 8 hours,
wherein the percutaneously absorptive preparation is an adhesive preparation, and
wherein a base matrix for the adhesive preparation is selected from the group consisting of an acrylic pressure sensitive adhesive, a silicone pressure sensitive adhesive and a rubber pressure sensitive adhesive.
2. The method of claim 1 , wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 16 hours.
3. The method of claim 1 , wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 8 hours after removal of the preparation from the skin.
4. A method for treating an allergic eye disease in a mammalian subject, which comprises applying a percutaneously absorptive preparation comprising 5 to 30% by weight of olopatadine or a pharmaceutically acceptable salt thereof to the skin surface including the surface of an eyelid of the subject, thereby causing transfer of a therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof from the preparation to an anterior ocular segment of the subject,
wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 8 hours,
wherein the percutaneously absorptive preparation is an adhesive preparation, and
wherein a base matrix for the adhesive preparation is selected from the group consisting of an acrylic pressure sensitive adhesive, a silicone pressure sensitive adhesive and a rubber pressure sensitive adhesive.
5. The method of claim 4 , wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 16 hours.
6. The method of claim 4 , wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 8 hours after removal of the preparation from the skin.
7. The method of claim 1 , wherein the adhesive preparation is applied to the skin surface for 0.5 to 24 hours.
8. A percutaneously absorptive preparation comprising 5 to 30% by weight of olopatadine or a pharmaceutically acceptable salt thereof for use in treating an allergic eye disease in a mammalian subject, which comprises applying it to the skin surface including the surface of an eyelid of the subject, thereby causing transfer of a therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof from the preparation to an anterior ocular segment of the subject,
wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 8 hours,
wherein the percutaneously absorptive preparation is an adhesive preparation, and
wherein a base matrix for the adhesive preparation is selected from the group consisting of an acrylic pressure sensitive adhesive, a silicone pressure sensitive adhesive and a rubber pressure sensitive adhesive.
9. The preparation of claim 8 , wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 16 hours.
10. The preparation of claim 8 , wherein the therapeutically effective amount of olopatadine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subject for at least 8 hours after removal of the preparation from the skin.
11. The preparation of claim 8 , which is applied to the skin surface for 0.5 to 24 hours.
12. The method of claim 4 , wherein the adhesive preparation is applied to the skin surface for 0.5 to 24 hours.